Streetbeat News

Regulatory

MMV

MultiMetaVerse Holdings Limited has received a notification from Nasdaq for non-compliance with the minimum bid price and market value requirements. The company plans to request a hearing to address these issues, failing which its shares may be delisted.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 8:36 pm

ATHA

Athira Pharma has received a non-compliance notice from Nasdaq, as per an SEC filing. This notice could have implications for the company's stock listing status.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 8:10 pm

FLUX

Flux Power Holdings, Inc. received a non-compliance letter from Nasdaq for not filing its Annual Report on time. The company has 60 days to submit a compliance plan and is working to file the report promptly.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 8:06 pm

BSX

Boston Scientific has received FDA approval for its new FARAWAVE NAV Ablation Catheter and FARAVIEW Software, enhancing its FARAPULSE Pulsed Field Ablation System for treating atrial fibrillation.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 8:02 pm

AXON

Axon announced that the Campbell Police Department in California received a groundbreaking FAA waiver for beyond visual line of sight (BVLOS) operations, allowing 24/7 drone use without visual observers. This enhances their Drone as a First Responder program, improving emergency response times and safety.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 7:44 pm

BNTX

BioNTech shares are experiencing a decline following the FDA's decision to place a clinical hold on their Phase 3 trial, PRESERVE-003.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 7:29 pm

BNTX

BioNTech SE and OncoC4 have announced that the FDA has placed a partial clinical hold on their Phase 3 trial, PRESERVE-003, due to varying results in different NSCLC patient populations. Enrollment of new patients is paused, but current participants will continue treatment.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 7:28 pm

LLY

The FDA announced it will not take action against GLP-1 compounders for certain violations as it reassesses the shortage of Eli Lilly's drug, Tirzepatide, used for weight loss and diabetes treatment.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 7:10 pm

TSLA

U.S. regulators are investigating Tesla's self-driving software after a fatal crash involving a Tesla vehicle. The probe focuses on whether the software adequately prompts drivers to retake control in dangerous situations.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 6:57 pm

ACHC

Acadia Healthcare is under investigation by the Veterans Affairs Department and other federal agencies for potential insurance fraud. The company is accused of holding patients longer than medically necessary to defraud government health insurance programs. Acadia is cooperating with authorities but denies any wrongdoing.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 6:55 pm